Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor
Jinesh Gheeya(National Cancer Institute), Javed Khan(Kent State University), Yves Pommier(National Cancer Institute), Jun S. Wei(Center for Cancer Research), Thomas S. Dexheimer(Frederick National Laboratory for Cancer Research), Peter A. Johansson(AstraZeneca (Sweden)), Young Song(University of British Columbia), Belhu Metaferia(National Cancer Institute), Qingrong Chen(National Cancer Institute), Jianbin He(National Institutes of Health)
Cited by 29
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673